Populationa | Genomic residuesb | Number of clones | Total nt. sequenced | Drug treatmentc | Mutationsd | Transitionse | Transversionse | Minimum mutation frequency (×10-3)f | Maximum mutation frequency (×10-3)g | Min/max ratio | Hh | ADi |
---|---|---|---|---|---|---|---|---|---|---|---|---|
No Drug p1 | 6609–8013 | 5 | 7025 | None | 2/2 | 0.50 | 0.50 | 0.28 | 0.28 | 1 | 0.58 | 0.50 |
AZCp1 | 6609–8013 | 5 | 7025 | [10 μg/ml] AZC | 1/1 | 0 | 1 | 0.14 | 0.14 | 1 | 0.31 | 0.25 |
FUp1 | 6609–8013 | 5 | 7025 | [200 μg/ml] FU | 2/2 | 1 | 0 | 0.28 | 0.28 | 1 | 0.58 | 0.50 |
No drug p25 | 6609–8013 | 5 | 7025 | None | 1/3 | 1 | 0 | 0.14 | 0.42 | 0.33 | 0.61 | 0.75 |
AZCp25 | 6609–8013 | 18 | 25290 | [10 μg/ml]AZC | 13/19 | 0.21 | 0.79 | 0.51 | 0.75 | 0.68 | 0.73 | 2.31 |
FUp25 | 6609–8013 | 5 | 7025 | [200 μg/ml] FU | 14/19 | 1 | 0 | 1.99 | 2.7 | 0.74 | 1 | 6.75 |
CAp35 | 6667–7997 | 21 | 27951 | None | 17/17 | 0.88 | 0.12 | 0.61 | 0.61 | 1 | 0.69 | 0.85 |
RA0p35 | 7150–8020 | 21 | 18291 | [800 μM] R, No drug | 17/68 | 0.75 | 0.25 | 0.93 | 3.71 | 0.25 | 1 | 3.62 |
RAp35 | 6667–7997 | 14 | 18634 | [500–800 μM] R | 55/139 | 0.91 | 0.09 | 2.95 | 7.46 | 0.39 | 1 | 13.15 (7.85) |
RAp45 | 6667–7997 | 12 | 15972 | [800 μM] R | 31/49 | 0.76 | 0.24 | 1.96 | 3.07 | 0.64 | 1 | 6.91 |
RAp60 | 6667–7997 | 14 | 18634 | [800–5000 μM] R | 55/80 | 0.97 | 0.02 | 2.95 | 4.29 | 0.69 | 1 | 7.62 |